Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

DOI

10.1111/bjh.17274

Type

Journal article

Publication Date

2021-02-01T00:00:00+00:00

Volume

192

Pages

e84 - e87

Keywords

Bendamustine, Brentuximab, Hodgkin lymphoma, Refractory, Relapse, Salvage, Adolescent, Adult, Antineoplastic Agents, Alkylating, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Bendamustine Hydrochloride, Brentuximab Vedotin, Child, Female, Hodgkin Disease, Humans, Male, Neoplasm Recurrence, Local, Treatment Outcome, Young Adult